Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. As a leader in rare diseases for 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. | Alexion, AstraZeneca’s Rare Disease group, was created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. For more than 30 years, Alexion’s mission has been to transform the lives of people affected by rare diseases through the development and delivery of innovative medicines, supportive technologies and healthcare services. Dedicated to continuing its mission as part of AstraZeneca, Alexion recognizes that patients and caregivers are people first, and by understanding their experiences, Alexion is better able to serve their unique needs. Alexion’s pioneering legacy in rare disease is rooted in being the first to translate the complex biology of the complement system into novel medicines. Alexion pushes boundaries to accelerate discovery of life-changing medicines. Headquartered in Boston, Massachusetts, Alexion has offices around the world and continues to expand its reach to benefit more people globally. For more information, please visit www.alexion.com. | Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. As a leader in rare diseases for 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology and ophthalmology. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries. For more information, please visit www.alexion.com.
AbbVie
AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. Please visit us at www.abbvie.com | Allergan, an AbbVie company, has dedicated 75 years to advancing eye care, launching 125+ products for prevalent eye conditions. We continue our commitment to helping ECPs deliver superior patient care through R&D, outreach programs, and educational support. | x | AbbVie is a global, research-based biopharmaceutical company that focuses on addressing complex and serious health issues. It develops innovative therapies and harnesses the power of advanced science to improve patients’ lives across a range of therapeutic areas including immunology, oncology, neuroscience, eye care, virology, and women’s health. Established as an independent entity in 2013 following its separation from Abbott Laboratories, AbbVie now operates in over 175 countries with a commitment to discover and deliver transformative solutions to the global community. With tens of thousands of employees, AbbVie strives to foster an inclusive and diverse work environment, adhering to its core values of agility, accountability, smart decision-making, and courageous communication. | AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn. | AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas. For more information about AbbVie, please visit us at www.abbvie.com. | We are AbbVie. A global Fortune 100 biopharmaceutical company creating life-changing medicines and first-in-kind solutions that make a real difference in people’s lives. Our 50,000+ employees across geographies, disciplines, and therapeutic areas put impact at the core of every decision. Leading with purpose, we work to build a more sustainable future for generations to come. Inclusive. Collaborative. Innovative. Since day one our inclusive culture has been the secret to our success. It’s reflected in everything we do and everything we offer. | AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas. For more information about AbbVie, please visit us at www.abbvie.com.
10ZiG Technology
10ZiG delivers secure, standardized, and centrally managed endpoints for healthcare organizations. Our Imprivata Ready thin clients, zero clients, and PC repurposing software enable safe access to clinical systems across VDI, DaaS, and cloud environments by reducing PHI exposure and supporting HIPAA-aligned security. 10ZiG helps healthcare leaders improve clinician experience while lowering TCO, risk, and operational complexity.